News Recap: Micron Technology, Yahoo! Inc, VIVUS, Arena Pharmaceuticals

Publishing & Media

Share Tweet

News Recap: Micron Technology, Yahoo! Inc, VIVUS, Arena Pharmaceuticals

NEW YORK, March 04, 2013 -, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Micron Technology, Yahoo! Inc, VIVUS, Arena Pharmaceuticals.

Micron Technology, Inc. (NASDAQ:MU) has said that the Tokyo district court has issued an order approving its acquisition of Japanese memory chipmaker Elpida after creditors agreed to the plan.

Is MU a Buy After The Recent Slump? Let’s find Out Here

In July, the Idaho company offered to buy Elpida for about $750 million in cash and to pay creditors a total of $1.75 billion in annual installments through 2019.  Micron is losing money as the PC industry is in shambles and wants to gain larger economies of scale which is possible with this acquisition.

A group of bondholders led by hedge funds Linden Advisors, Owl Creek Asset Management and Taconic Capital Advisors have also been interested in the company for some time and they have filed a suit at the U.S. Bankruptcy Court in Delaware. Micron and Elpida now need approval from this court.

Elpida was driven into bankruptcy due to falling chip sales and foreign competition.  The acquisition would make Micron the No. 2 global supplier of DRAM chips.

Meanwhile, Yahoo! Inc.(NASDAQ:YHOO) CEO Marissa Mayer is very much in the news of late thanks to her new rule that says all employees have to work from office; no more work-from-home.

Will YHOO Continue To Hit New Highs? Find out Here

This has drawn a lot of flak from all the work-from home folk who defend themselves saying that working from home does not hinder efficiency in any way, helps them save time on unnecessary commuting and helps achieve a better work-life balance. 

The women who often have to bear household and children-related responsibilities will be affected the most. Many Yahoo work-from-home female employees may be feeling that Mayer expects all of them to live up to her formidable standards- her two-week maternity leave speaks volumes.

However, everybody is so engrossed in this debate, that they have lost what Mayer is actually saying and that she may have a valid reason for it. She believes that as of now, Yahoo needs its employees in the office working together. Yahoo work-from-homes who believe otherwise can start looking out…. for another job!

There are chances that VIVUS, Inc.(NASDAQ:VVUS) will be lowering its Qsymia, just a few months following its commercialization. According to Andrew Berens of Bloomberg Industries, Vivus, will begin offering medium does of Qsymia for 30 days for maximum out-of-pocket cost of $75.Aside from the present 14-day free trial program of Qsymia’s low does, the patients will also be able to get therapy for six weeks at a cost of $75, which is below

the list price by 70%. This act by Vivus might pose as a threat for companies like Eisai's Belviq and Arena Pharmaceutical who are competitors of Qsymia. The wholesale cost of Belviq for therapy will amount to $200 for four weeks.  According to Berens, the pharmacy mark-up will result in higher retail costs for Belviq. 

How Should Investors Trade VVUS After The Recent Plunge? Get Free Trend Analysis Here

Shares of Vivus were down by 2% on Monday.  According to the reports of Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), the loss for the fourth quarter was smaller but the company stated that it was still waiting for the decision of the federal regulators regarding the status of its drug for weight loss called Belviq. 

Is ARNA a Buy After Today’s Slump? Get Free Research report Here

On 27th June, Belviq was approved by the Food and Drug Administration but the drug has still not gone on sale. According to the proposition of the Drug Enforcement Administration, Belviq can be classified as a Schedule IV controlled substance, which actually means that it h s comparatively low potential for abuse. Arena, along with its partner Eisai Co., will not be able to go ahead and market the drug unless and until they obtain the Pharmaceutical’ approval.

There is no clarity as to when that will happen. Arena Pharmaceutical’s shares lost 35 cents and came down to $7.99 in morning trading. According to Arena, there was a loss of $21.3 million in the fourth quarter which was comparatively lower than $23.7 million in the fourth quarter of 2011.

About’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.


1419 Westwood Blvd Los Angeles, CA
[email protected]